Roberto Leon Ferre, MD
Medical Oncology · Rochester, MNNPI 1427361377
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,293 of the $28,194 with a category attached, or 96.8%. Gilead accounts for 61.3% of it on its own, with 2 other manufacturers making up the rest.
Across 24 payments — averaging $1174.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$17K
- AstraZeneca$9K
- Merck$2K
Across 17 payments — averaging $37,240 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$572K
- Pfizer$40K
- Immunomedics, Inc.$17K
- Gilead$5K
What the payments were for
- Consulting fees$27,29397%
- Food & beverage$8723%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 14 | $17,292 |
| AstraZeneca | 9 | $8,767 |
| Merck | 1 | $2,135 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,194 in reported general payments places this provider in the 75th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 20 | $302,532 |
| VerzenioAbemaciclib | 19 | $277,907 |
| KisqaliRibociclib Succinate | 13 | $176,777 |
| Letrozole | 99 | $1,836 |
| Olanzapine | 14 | $327 |
| Tamoxifen Citrate | 11 | $230 |
| Anastrozole | 12 | $175 |
| Ondansetron Hcl | 23 | $174 |
| Dexamethasone | 24 | $155 |
| Prochlorperazine Maleate | 24 | $145 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Rochester
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Thorvardur HalfdanarsonRochester$86K
- Harry YoonRochester$69K
- Karthik GiridharRochester$66K
- Joleen HubbardRochester$59K
- Lionel Aurelien Kankeu FonkouaRochester$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.